Keros Therapeutics, Inc.
KROS
$9.93
-$0.14-1.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -84.55% | 6,774.96% | 37,798.31% | 85,820.30% | 91,657.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -84.55% | 6,774.96% | 37,798.31% | 85,820.30% | 91,657.69% |
| Cost of Revenue | -47.34% | -25.39% | -4.91% | 24.38% | 29.25% |
| Gross Profit | -308.11% | 167.33% | 154.21% | 130.49% | 121.54% |
| SG&A Expenses | 13.57% | 14.96% | 16.78% | 18.02% | 9.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.26% | -17.72% | -0.76% | 23.08% | 25.16% |
| Operating Income | -969.33% | 132.10% | 121.36% | 100.17% | 94.26% |
| Income Before Tax | -720.44% | 149.13% | 139.18% | 116.00% | 109.08% |
| Income Tax Expenses | -149.89% | 1,527.67% | -- | -- | -- |
| Earnings from Continuing Operations | -2,121.49% | 146.44% | 135.50% | 111.17% | 102.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2,121.49% | 146.44% | 135.50% | 111.17% | 102.63% |
| EBIT | -969.33% | 132.10% | 121.36% | 100.17% | 94.26% |
| EBITDA | -1,105.68% | 133.00% | 122.19% | 100.89% | 94.95% |
| EPS Basic | -1,998.67% | 137.16% | 130.43% | 106.91% | 97.21% |
| Normalized Basic EPS | -2,917.91% | 139.33% | 133.60% | 110.82% | 102.17% |
| EPS Diluted | -1,532.85% | 136.24% | 129.54% | 104.78% | 97.15% |
| Normalized Diluted EPS | -4,749.88% | 138.45% | 132.75% | 109.96% | 101.32% |
| Average Basic Shares Outstanding | -17.16% | -0.48% | 16.22% | 20.91% | 23.59% |
| Average Diluted Shares Outstanding | -17.41% | -0.17% | 16.55% | 21.26% | 23.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |